100 EUR discount on all conferences, arranged by EBD Group.

Lytix Biopharma has announced promising interim results from an ongoing investigator-initiated Phase 2 NeoLIPA study evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab as neoadjuvant therapy in resectable melanoma.

Authera has received funding from the Research Council of Norway through the Innovation Project for the Industrial Sector.

Anders Tuv’s varied background as an investor, founder, and company builder has taken him to the very center of the multidisciplinary nature of creating a life science company. As Managing Director at Radforsk Invest he truly enjoys shaping strategies and helping startups implement and realize innovations.

Experts from across the Nordic region gathered in Copenhagen November 11, 2025, for Nordic Pharmacovigilance Day 2025, a full-day conference that brought together professionals, academics and industry leaders to discuss the latest developments in drug safety, artificial intelligence and regulatory best practices.